Editorial: Don’t rush to rehabilitate Hwang
By Editorial,
Nature
| 01. 21. 2014
An article published on Nature’s website last week has created quite a buzz in South Korea. It details efforts by former Seoul National University cloning specialist Woo Suk Hwang to rehabilitate his scientific career after he was found in 2006 to have been involved in fraud. Some in South Korea are taking the article as a sign that Hwang is now producing great science and is once again lauded by the scientific community. Stock prices of companies with connections to Hwang’s work have apparently jumped. It is as if many of the people talking and writing about the article have not read it. They and others can do so now if they wish: it appears as a News Feature on page 468.
As readers will see, the article is not a show of support for Hwang’s research. Nor is it an attack. It is the story of a rare event: a scientist attempting with some success to dig himself out from the depths of ignominy. It is a journalistic exercise, not a scientific endorsement. And it was commissioned to...
Related Articles
By Liyan Qi and Jonathan Cheng, The Wall Street Journal | 03.26.2025
photo via Wikimedia Commons licensed under CC by 3.0
Chinese scientist He Jiankui set off global outrage and landed in prison after he skirted ethical guidelines and claimed he had produced genetically modified babies designed to resist HIV infection.
Now, the self-styled ...
By Peter Wehling, Tino Plümecke, and Isabelle Bartram
| 03.26.2025
This article was originally published as “Soziogenomik und polygene Scores” in issue 272 (February 2025) of the German-language journal Gen-ethischer Informationsdienst (GID); translated by the authors.
In mid-November 2024, the British organization Hope not Hate published its investigative research ‘Inside the Eugenics Revival’. In addition to documentating an active international “race research” network, the investigation also brought to light the existence of a US start-up that offers eugenic embryo selection. Heliospect Genomics aims to enable wealthy couples to...
By Carsten T. Charlesworth, Henry T. Greely, and Hiromitsu Nakauchi, MIT Technology Review | 03.25.2025
Why do we hear about medical breakthroughs in mice, but rarely see them translate into cures for human disease? Why do so few drugs that enter clinical trials receive regulatory approval? And why is the waiting list for organ transplantation...
By Anna Louie Sussman, The New York Times | 03.25.2025
On June 24, 2022, the same day the Supreme Court issued its decision in Dobbs v. Jackson Women’s Health Organization, I received a call from the fertility clinic where I’d been undergoing in vitro fertilization, informing me that seven of...